Normal thymic uptake of 2-deoxy-2[F-18]fluoro-D-glucose

Thymic tissue is not evident on high-resolution computed tomography and [¹⁸F]fluoro-deoxy-glucose positron emission tomography scans of aviraemic HIV patients with poor recovery of CD4⁺ T cells

Some previously immunodeficient HIV patients responding to antiretroviral therapy display poor recovery of CD4⁺ T cells. Evaluation of the contribution of thymic function requires sensitive detection and quantitation of metabolically active thymic tissue. We describe patients with low but detectable thymopoiesis assessed as circulating CD4⁺ naive T cells expressing CD31. High-resolution computed tomography and PET scans found no residual thymic tissue even though metabolic activity was demonstrable by PET in lymph nodes.

[Thymic uptake of 18FFDG following radioiodine ablation therapy]

We report the case of a 47 year-old woman with a history of non-Hodgkin's lymphoma. During the course of her disease, we performed various (18F)FDG PET/CT that identified several significant incidental findings. First, we incidentally identified a hypermetabolic nodule in the left thyroid lobe, whose final diagnosis was differentiated thyroid carcinoma. Second, metabolic activity was visualized in the thymus secondary to ablative treatment with radioiodine. This uptake disappeared in subsequent studies. Several papers have reported thymic rebound following chemotherapy but we have found only one case report of (18F)FDG uptake after radioiodine treatment. On the other hand, this case is of interest because it supports the benefit of studying the hypermetabolic thyroid nodules incidentally detected on the PET/CT performed for other reasons.

Increased serum thyroglobulin levels and negative imaging in thyroid cancer patients: are there sources of benign secretion? A speculative short review

After thyroidectomy and 131I ablation for differentiated thyroid cancer (DTC), serum thyroglobulin (Tg) became a sensitive marker of residual disease. It is not uncommon to find patients at follow-up with persistent serum Tg levels and no other clinical or imaging evidence for the disease. The vast majority of these patients, most probably, have occult foci of disease, often in minute cervical lymph nodes. A review of the literature including papers published on PubMed/Medline until June 2010 was made. In this study we speculated that a minority of patients who had undergone surgery for differentiated thyroid cancer might have benign sources of Tg secretion at follow-up. These sources may be foci of radio-resistant ectopic thyroid tissue or a thyroid stimulating hormone-stimulated thymus.

Positron emission tomography/computed tomography potential pitfalls and artifacts

With the recent use of 18-fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) for tumor staging and treatment response, it is important to recognize many pitfalls, artifacts, and benign uptakes that are commonly encountered. Normal physiology can explain many regions of increased FDG activity, as well as incidental benign tumors and benign metabolic conditions. Recognition of characterization of benign causes and physiologic variants for FDG uptake are discussed to avoid improper characterization as a malignancy. A basic understanding of PET/computed tomographic physics is also discussed, in relation to attenuation correction artifacts caused by metallic implants and contrast agents in the gastrointestinal tract, as well as artifacts caused in fused images due to patient motion. Also presented is the rationale for expected, benign uptake in various metabolic diseases, as well as pharmacologic methods for decreasing the artifacts caused by metabolic diseases. PET/computed tomographic evaluation of the thyroid, thymus, adrenal adenomas, uterus and ovaries, infection/inflammatory changes, and postradiation/chemotherapy changes are also discussed, with expected normal changes, as well as pitfalls and artifacts.

Detection of age-related changes in thoracic structure and function by computed tomography, magnetic resonance imaging, and positron emission tomography

It is useful to understand the normal changes in structure and function in the thorax that occur with age. Thus, we present the following quantitative preliminary data obtained from retrospective quantitative analysis of computed tomography (CT) and positron emission tomography (PET) examinations in subjects 0 to 90 years of age: Mean lung standard uptake values were found to significantly increase with increasing age and with increasing body mass index (BMI). Mean lung attenuation was seen to statistically significantly decrease with increasing age in subjects who had a CT scan, had a nonsignificant tendency to decrease with increasing age in subjects with a PET/CT scan, had a nonsignificant tendency to increase with increasing BMI, and was seen to significantly increase with increasing mean lung standard uptake values. Mean lung volumes were not noted to significantly change with increasing age in adult subjects whether or not they were normalized to the craniocaudal thoracic lengths, although mean lung volumes significantly increased with increasing age in pediatric subjects. Mean lung volumes had a nonsignificant tendency to decrease with increasing BMI, although normalized mean lung volumes significantly decreased with increasing BMI. Lung metabolic volumetric products were not noted to significantly change with increasing BMI or with increasing age. In this work, we also review the literature regarding normal structural and functional changes in the thorax with age.

Should 'low-risk' thyroid cancer patients with residual thyroglobulin be re-treated with iodine 131?

OBJECTIVE

The American consensus statement on patients with low-risk thyroid cancer, published in 2003, suggests repeat (131)I therapy if the thyroglobulin value is elevated at first follow-up. We evaluated this strategy in our practice.

METHODS

Among 407 patients with thyroid cancer who had total thyroidectomy and (131)I ablation between January 2000 and December 2003, 12 patients with stage I thyroid cancer (any tumour (T), any node (N), metastasis (M)0 if < 45 years or T1, N0, M0 if > 45 years), were re-treated on the basis of their thyroglobulin level at first follow-up. Mean patient age was 32.8 years. None of them had a T4 tumour. Thyroglobulin levels after thyroid hormone withdrawal 'off-T4' ranged between 4.5 and 251 ng/ml (median 8). One to four courses of 3.7 GBq (131)I were given.

RESULTS

Three patients had a negative (131)I therapy scan and an uneventful course. Two patients had slight residual uptake only in the thyroid bed and negative ultrasound examination. Four patients had isolated (131)I uptake in the mediastinal region. No abnormalities were found on complementary mediastinal imaging. This finding was interpreted as benign (131)I thymic uptake. The last three patients also had mediastinal thymic uptake associated with a slight thyroid bed uptake. One patient had a gradual increase in the thyroglobulin level, and underwent resection of nonfunctioning neck lymph nodes. Thyroglobulin levels declined in all other patients.

CONCLUSIONS

No distant lesions were found in a group of young 'low-risk' thyroid cancer patients given empirical (131)I therapy for residual thyroglobulin. When blind (131)I therapy shows no uptake, or uptake limited to the thymus, (131)I therapy should not be repeated. The authors also briefly discuss the hypothesis that enhanced thymus might be a source of benign thyroglobulin secretion.

Intense 18-fluorodeoxyglucose uptake by the thymus on PET scan does not necessarily herald recurrence of thyroid carcinoma

This is the first report of intense fluorodeoxyglucose positron emission tomography (FDG-PET) uptake secondary to thymic hyperplasia during follow-up for thyroid carcinoma. A 36-yr-old woman underwent thyroidectomy for a papillary carcinoma measuring 4 cm in diameter. After two doses of radioiodine, thyroglobulin (Tg) remained detectable following recombinant human TSH (rhTSH) stimulation. A whole body scan (WBS) was negative. On computed tomography (CT) scan, a slightly lobulated thymus was visualized. PET scan showed intense thymic uptake. Following resection, anatomo-pathological analysis showed homogenous hyperplastic thymic gland without neoplastic cells. Two months later, under levothyroxin (L-T4) substitution, Tg was no longer detectable and PET scanning did not show any 18-FDG uptake. This observation suggests that thymic FDG uptake does not necessarily herald recurrence of thyroid carcinoma and must be interpreted with caution in such a setting. Other conditions associated with abnormal uptake by hyperplastic thymus must also be envisaged.

Evolving role of positron emission tomography in the management of patients with inflammatory and other benign disorders

Fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) has evolved from a research imaging modality assessing brain function in physiologic and pathologic states to a pure clinical necessity. It has been successfully used for diagnosing, staging, and monitoring a variety of malignancies. FDG-PET imaging also is evolving into a powerful imaging modality that can be effectively used for the diagnosis and monitoring of a certain nononcological diseases. PET has been shown to be very useful in the diagnosis of osteomyelitis, painful prostheses, sarcoidosis, fever of unknown etiology, and acquired immunodeficiency syndrome. Based on recent observations, several other disorders, such as environment-induced lung diseases, atherosclerosis, vasculitis, back pain, transplantation, and blood clot, can be successfully assessed with this technique. With the development and the introduction of several new PET radiotracers, it is expected that PET will secure a major role in the management of patients with inflammatory and other benign disorders.

Imaging Evaluation of Pediatric Mediastinal Masses

Mediastinal masses in children are a heterogeneous group of asymptomatic to potentially life-threatening congenital, infectious, or neoplastic lesions that can present complex diagnostic and therapeutic dilemmas. This article presents the imaging features of the common mediastinal masses seen in the pediatric population. Classification of the masses is performed according to the traditional mediastinal compartment model, consisting of the anterior, middle, and posterior mediastinum. This scheme facilitates differentiation of the variety of disorders.

Spectrum of Thymic Uptake at18F-FDG PET

Fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) has emerged as a strong diagnostic tool for the diagnosis and staging of neoplasms. Uptake in the thymus at (18)F-FDG PET complicates the assessment of mediastinal involvement by tumor in children and young adults. Increased thymic (18)F-FDG uptake may represent normal physiologic uptake but may also indicate the presence of thymic hyperplasia, lymphomatous infiltration, primary thymic neoplasm, or metastatic disease. Familiarity with the patterns of (18)F-FDG uptake that characterize these pathologic conditions is crucial to the interpretation of PET findings in the thymus. In addition, awareness of the subsets of patients in whom physiologic uptake may be seen and of the normal morphologic features and (18)F-FDG PET appearance of the thymus, along with a general sense of the upper limits of metabolic activity for physiologic thymic uptake, will aid in differentiating between physiologic thymic uptake and mediastinal disease. In equivocal cases, correlation with morphologic data from computed tomography or magnetic resonance imaging will likely continue to play a key role in diagnosis and will aid in differentiating benign thymic uptake from malignancy.

Normal variants in [18F]-fluorodeoxyglucose PET imaging

The number of fluorodeoxyglucose PET applications is increasing. In the process of reading fluorodeoxyglucose-PET scans, nuclear medicine physicians encounter a wide variety of normal findings, which must be recognized to determine the best management for patients. It is important to recognize and understand normal variants to avoid misinterpretation of more serious pathology. This article reviews different patterns of physiologic fluorodeoxyglucose uptake including changes with age.

Implications of mediastinal uptake of131I with regard to surgery in patients with differentiated thyroid carcinoma

BACKGROUND

Findings of mediastinal uptake of 131I after surgical treatment for differentiated thyroid carcinoma (DTC) are common, especially in young patients. Given the frequency of false-positive findings, a protocol for diagnostic and therapeutic strategies would be useful. With the goal of accurately selecting management strategies, the authors analyzed their data and data found elsewhere in the literature for correlations with the incidence of mediastinal 131I uptake and with treatment for patients exhibiting such 131I uptake.

METHODS

All patients with DTC who were treated between 1978 and 2000 at Groningen University Hospital (Groningen, The Netherlands) and who received adjuvant 131I ablation therapy were included in the current analysis, which involved retrospective review of all relevant data.

RESULTS

Five hundred four patients with DTC initially underwent total thyroidectomy, with additional 131I ablation performed for 489 of these patients. In 48 of 489 patients (9.8%), 131I uptake was seen in the mediastinum on a posttreatment scan. Analysis of those 48 patients and of cases in the literature demonstrated that serum thyroglobulin levels, risk status, and the presence of thymus on radiologic images were important in the surgical decision-making process.

CONCLUSIONS

Mediastinal uptake of 131I on posttreatment scans was found in approximately 10% of patients after total thyroidectomy for DTC. Based on the current data and the data presented in the literature, the authors developed a flow chart for determining appropriate treatment strategies, which included mediastinal dissection for high-risk patients and for patients with serum thyroglobulin levels > 10 ng/mL.

Thymic uptake of radiopharmaceuticals

The thymus, as the site of T-cell differentiation, plays a critical role in the development of the immune system. The gland increases in weight until puberty and then is slowly replaced by fat. Various radiopharmaceuticals can localize to the thymus before it involutes. This pictorial presentation reviews the appearance and proposed mechanisms of thymic uptake of Ga-67 citrate, F-18 fluorodeoxyglucose, radioiodine, and In-111 pentetreotide.

Limitations of PET for imaging lymphoma

The uptake of fluorine-18 fluorodeoxyglucose (FDG) is increased in processes with enhanced glycolysis, including malignancy. It is this property of FDG which is exploited in positron emission tomography (PET) imaging for lymphoma. FDG, whilst a good oncology tracer, is not perfect and there are limitations to its use. FDG may have low uptake in some types of lymphoma, predominantly low-grade lymphomas. High physiological uptake may occur within the bowel, urinary tract, muscle, salivary glands and lymphoid tissue. FDG is not specific for malignancy and increased uptake occurs in benign conditions with increased glycolysis such as infection, inflammation and granulomatous disease. Benign conditions usually have lower uptake than malignancy but there is overlap. These limitations of FDG mean that tumour may be 'missed', 'masked' or 'mimicked' by other pathology. These limitations are described in this article and methods to circumvent them where possible are discussed. These include performing baseline scans at presentation with lymphoma for comparison with post-treatment scans, simple manoeuvres to reduce physiological uptake such as administration of frusemide and diazepam and remaining alert to the possibility of alternative pathology in immunosuppressed patients. Patients with disease secondary to human immunodeficiency virus are a particular challenge in this regard as they often have dual or multiple pathology. One of the most important skills in PET reporting may be to recognise its limitations and be clear when a definitive answer cannot be given to the referring clinician's question. This may require using PET to direct the clinician to biopsy the site most likely to yield the correct diagnosis.

Thymic enlargement and FDG uptake in three patients: CT and FDG positron emission tomography correlated with pathology

OBJECTIVE

Our purpose was to describe three adult patients in whom we found increased thymic uptake of FDG on positron emission tomography and thymic enlargement with convex lateral margins on CT. Subsequent biopsy or resection showed normal thymic tissue.

CONCLUSION

In three adults, we found a physiologic uptake of FDG by the thymus with standardized uptake values in the range of thymic neoplasia.

Positron emission tomography imaging in nonmalignant thoracic disorders

The role of the fluorodeoxyglucose (FDG) technique positron emission tomography (PET) is well established in the management of patients with lung cancer. Increasingly, it is becoming evident that FDG-PET can be effectively employed to diagnose a variety of benign pulmonary disorders. Knowledge of such applications further expands the domain of this powerful modality and further improves the ability to differentiate benign from malignant diseases of the chest. We describe pertinent technical factors that substantially contribute to optimal imaging of the thoracic structures. Particularly, the complementary role of attenuation correction (AC) to that of non-AC images is emphasized. We further outline the need for and the state of the art for co-registration of PET and anatomic images for diagnostic and therapeutic purposes. We then review patterns of physiologic uptake of FDG in thoracic structures, including the lung, the heart, the aorta and large arteries, esophagus, thymus, trachea, thoracic muscles, bone marrow, and joints and alterations following radiation therapy to the thorax. A great deal of information is provided with regard to differentiating benign from malignant nodules and in particular, we emphasize the role of dual time point imaging and partial volume correction for accurate assessment of such lesions. Following a brief review of the diagnostic issues related to the assessment of mediastinal adenopathies, the role of FDG-PET imaging in environment-induced lung diseases, including pneumoconiosis, smoking, and asthma are described. A large body of information is provided about the role of this technology in the management of patients with suspected infection and inflammation of the lungs such as acquired immunodeficiency syndrome, fever of unknown origin, sarcoidosis, chronic granulomatous disease and monitoring the disease process and response to therapy. Finally, the value of FDG-PET in differentiating benign from malignant diseases of the pleura including asbestosis-related disorders is described at the conclusion of this comprehensive review.

FDG uptake in the morphologically normal thymus: comparison of FDG positron emission tomography and CT

The purpose of this study was to evaluate the correlation between fluorine-18 fluorodeoxyglucose (FDG) thymic uptake and a normal appearing thymus on CT. Non-attenuation corrected FDG positron emission tomography (PET) data from 94 young persons (mean age 25.4 years, range 18-29 years) with a normal thymus diagnosed on CT were retrospectively evaluated. No subject had clinical symptoms suggestive of thymus-related disease or mediastinal tumour (follow-up period 6-69 months). PET images were visually assessed and the count ratio between the thymus and the lung (T/L ratio) was calculated. Increased FDG uptake occurred in 32 (34%) subjects. In these 32 cases, the T/L ratio was 2.86+/-0.49 (range 2.02-3.99). In 86 subjects whose CT images were available to calculate the CT attenuation of the thymus (CAT), the CAT value was -17.5+/-45.7 HU (range -103.6 HU to 79.9 HU). The T/L ratio correlated with the CAT value (r=0.58). CAT values in subjects with positive PET findings were significantly higher than CAT values in subjects with negative PET findings (p<0.001, unpaired t-test). These results suggest that even in young adults, if the thymus has a relatively high CT attenuation value, the presence of physiological thymic uptake in FDG-PET is a normal variant. In this study, the diagnosis of normal thymus was based on CT appearance and clinical course. Further studies are needed to clarify the relationship between histopathology and FDG uptake in the thymus.

Similar Pelvic Abnormalities on FDG Positron Emission Tomography of Different Origins

Fluorodeoxyglucose positron emission tomography (FDG PET) has been used extensively to detect and stage various cancers. However, normal variation and inflammatory lesions may lead to false-positive interpretations of PET findings. The authors report three cases of increased pelvic FDG uptake with differing origins. Although the findings are similar, a postpartum uterus, lymphoma, and a bleeding uterus caused pelvic FDG uptake in these patients. Interestingly, of these three patients, the patient with lymphoma had the lowest level of FDG uptake. Clinical correlation is needed for the accurate interpretation of FDG-PET findings.

18F-FDG Uptake in the Anterior Mediastinum. Physiologic Thymic Uptake or Disease?

Purpose: We reviewed 18F-fluorodeoxyglucose (18F-FDG) studies to determine the frequency of thymic visualization, to characterize this uptake to facilitate differentiation from disease, and to ascertain effects of therapy on visualization.Methods: Hybrid positron emission tomography images performed on 14 patients with known or suspected malignancy before therapy, and on six of the patients after treatment, were reviewed. Mediastinal uptake was characterized by location, contour and intensity.Results: Thymic uptake seen in five patients, 13-16-years-old, was characterized by an anterior midline location, regular contours, and a mean uptake ration of 2.5, and involved large glands. In five patients with mediastinal disease, 16-23-years-old, uptake was more posterior and eccentric in location with irregular borders and a mean uptake ratio of 4.3. One patient had anterior (thymic) and posterior (disease) mediastinal uptake. Three patients, 15-22-years-old, without disease and small thymus glands had no uptake. Five patients, including two with baseline uptake, showed no thymic uptake subsequently. One patient, negative initially, had thymic uptake five months after therapy.Conclusions: Thymic 18F-FDG uptake occurs in younger patients, before or after treatment, and is associated with larger glands. Its midline anterior mediastinal location and mild intensity should facilitate discrimination from disease.